Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to determine the efficacy of an investigational therapy
called DCVax(R)-L in patients with newly diagnosed GBM for whom surgery is indicated.
Patients must enter screening at a participating site prior to surgical resection of the
tumor. Patients will receive the standard of care, including radiation and Temodar therapy
and two out of three will additionally receive DCVax-L, with the remaining one third
receiving a placebo. Patients randomized to the placebo arm will have the option to receive
DCVax-L in a crossover arm upon documented disease progression. (note: DCVax-L when used for
patients with brain cancer is sometimes also referred to as DCVax-Brain)